Boston Business Journal -- Woburn's BioTrove Inc., which is planning to go public, disclosed Thursday that revenue in the first quarter surged surged 89 percent, but the company continues to rack up losses from research and development costs. BioTrove develops drug discovery and molecular diagnostic tools for major biopharmaceutical companies. The company filed for an initial public offering about two months ago.
